Our analysis based on public TCGA database implicates APOBEC3B copy number variation (CNV) is amplified (gistic2 thresholded CNV > = 1 or gistic2 CNV > = 0.1) in 29.9% (304 of 1017) NSCLC samples, and APOBEC3B CNV significantly positively correlates with APOBEC3B mRNA (Fig. 1c), implicating CNV amplification is one driving force for APOBEC3B mRNA upregulation during cancer evolution. This evidence concerns the gene APOBEC3B and cancer.